Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2271-2276

  Zhou, Fan ^a,b   Ling, Chenhui ^b   Guo, Lieping ^b   Wei, Wei ^b   Li, Lu ^b   Shi, Haotian ^b   Hou, Jian ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Zhabei District Central Hospital   (China)

Author keywords

Cyclophosphamide; Heart failure; Prednisone; Relapsed refractory multiple myeloma

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; PREDNISONE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMNOLENCE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM GRADING; NEOPLASM STAGING; PREDNISONE; RECURRENCE; TREATMENT OUTCOME;

EID: 84925292667     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.887711     Document Type: Article

References (28)

1. Vázquez FJ, Funtowicz G, Rivello HG, et al. Nodular hepatic lesions secondary to multiple myeloma. Medicina (B Aires) 2010;70:311-315.
2. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
4. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-728.
5. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
6. Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008;49:447-450.
7. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-337.
8. Herrlinger U, Rieger J, Steinbach JP, et al. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 2005;71:295-299.
9. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
10. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
11. Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 2010;28:723-730.
12. Nicolas P, Antoine A, Guido B. Cyclophosphamide-based metronomic chemotherapy:After 10 years of experience, where do we stand and where are going? Crit Rev Oncol Hematol 2012;82:40-50.
13. Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone:an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578-1582.
14. Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007;12:99-106.
15. Zhou F, Guo LP, Shi HT, et al. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:51-55.
16. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
17. th ed. Boston, MA: Little, Brown & Co, 1994. pp 253-256.
18. Stacey JW, Alan HB, Robert C, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002;144:834-839.
19. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf
20. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-157.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
22. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6:295-300.
23. Rickard J, Cheng A, Spragg D, et al. Durability of survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of "non-responders". Heart Rhythm 11/2013. DOI:10.1016/j.hrthm.2013.11.025. [Internet]
24. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:118-147.
25. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
26. Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 2002;14:238-242.
27. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
28. Robin J, Fintel B, Pikovskaya O, et al. Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature. J Med Case Rep 2008;2:229-234.